Progenics Pharmaceuticals Inc (PGNX)

7.85
0.03 0.38
NASDAQ : Health Care
Prev Close 7.88
Open 7.97
Day Low/High 7.82 / 7.99
52 Wk Low/High 3.61 / 11.15
Volume 154.23K
Avg Volume 1.47M
Exchange NASDAQ
Shares Outstanding 70.19M
Market Cap 553.80M
EPS 0.10
P/E Ratio 52.60
Div & Yield N.A. (N.A)

Latest News

Short Interest Drops 23% For PGNX

Short Interest Drops 23% For PGNX

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,093,733 share decrease in total short interest for Progenics Pharmaceuticals, Inc. , to 7,048,887, a decrease of 22.90% since 03/15/2017.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of November 17th Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the November 17th expiration.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)

First Week of March 17th Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the March 17th expiration.

Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options

Commit To Buy Progenics Pharmaceuticals At $7, Earn 12.9% Using Options

Investors considering a purchase of Progenics Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $8.79/share, might benefit from considering selling puts among the alternative strategies at their disposal.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHP, ARCX, ATNI, HTGC, MGM, PGNX, PGRE, SGMS, SYF, WABC Downgrades: ABDC, ARCC, ARII, BOJA, CTLT, FSM, GEL, H, KMPR, LBTYA, LBTYB, LBTYK, TSCO Initiations: PEN, PSTG Read on to get TheStreet Quant Ratings' detailed report:

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Provides Non-Dilutive Funding to Advance Late-Stage Oncology Portfolio

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.